[go: up one dir, main page]

PE20181515A1 - Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales - Google Patents

Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales

Info

Publication number
PE20181515A1
PE20181515A1 PE2018001063A PE2018001063A PE20181515A1 PE 20181515 A1 PE20181515 A1 PE 20181515A1 PE 2018001063 A PE2018001063 A PE 2018001063A PE 2018001063 A PE2018001063 A PE 2018001063A PE 20181515 A1 PE20181515 A1 PE 20181515A1
Authority
PE
Peru
Prior art keywords
wnt signaling
tumor cells
polypeptides
methods
biparatopic polypeptides
Prior art date
Application number
PE2018001063A
Other languages
English (en)
Inventor
Vittoria Zinzalla
Klaus-Peter Kuenkele
Marie-Ange Buyse
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20181515A1 publication Critical patent/PE20181515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion proporciona polipeptidos de fijacion de reaccion cruzada con LRP5/LRP6 biparatopicos novedosos y, mas especificamente, constructos de dominio variable unico de inmunoglobulina de reaccion cruzada con LRP5/LRP6 biparatopicos novedosos que pueden inhibir las vias de senalizacion Wnt. La invencion tambien se refiere a secuencias especificas de estos polipeptidos, metodos para su fabricacion y metodos para usarlos, que incluyen metodos para el tratamiento de enfermedades, tales como cancer.
PE2018001063A 2015-12-04 2016-12-02 Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales PE20181515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15197999 2015-12-04

Publications (1)

Publication Number Publication Date
PE20181515A1 true PE20181515A1 (es) 2018-09-21

Family

ID=54782606

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001063A PE20181515A1 (es) 2015-12-04 2016-12-02 Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales

Country Status (34)

Country Link
US (2) US10597449B2 (es)
EP (2) EP3383425B1 (es)
JP (2) JP6728355B2 (es)
KR (1) KR102802241B1 (es)
CN (1) CN108289943B (es)
AR (1) AR106949A1 (es)
AU (1) AU2016363787B2 (es)
BR (1) BR112018010537A2 (es)
CA (1) CA3006235A1 (es)
CL (1) CL2018001384A1 (es)
CO (1) CO2018005680A2 (es)
CY (1) CY1123454T1 (es)
DK (1) DK3383425T3 (es)
EA (1) EA201891331A1 (es)
ES (1) ES2821099T3 (es)
HR (1) HRP20201528T1 (es)
HU (1) HUE051777T2 (es)
IL (1) IL259119B (es)
LT (1) LT3383425T (es)
MA (2) MA54648A (es)
MX (1) MX380414B (es)
MY (1) MY200933A (es)
NZ (1) NZ742037A (es)
PE (1) PE20181515A1 (es)
PH (1) PH12018501155B1 (es)
PL (1) PL3383425T3 (es)
PT (1) PT3383425T (es)
RS (1) RS60823B1 (es)
SA (1) SA518391728B1 (es)
SG (1) SG11201804510PA (es)
SI (1) SI3383425T1 (es)
TW (1) TWI734719B (es)
UA (1) UA122079C2 (es)
WO (1) WO2017093478A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6397335B2 (ja) 2012-02-28 2018-09-26 ノバルティス アーゲー ＲＮＦ４３変異ステータスを利用したＷｎｔシグナル伝達阻害剤の投与のためのがん患者選択法
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
PE20181515A1 (es) * 2015-12-04 2018-09-21 Boehringer Ingelheim Int Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7216024B2 (ja) * 2017-05-31 2023-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド
KR20250056192A (ko) 2017-08-07 2025-04-25 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
SG11202004907SA (en) 2017-11-29 2020-06-29 Univ Texas Compositions and methods for cancer therapy
CA3085782A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
JP2021529796A (ja) * 2018-07-05 2021-11-04 スロゼン， インコーポレイテッド 多特異性Ｗｎｔ代替分子及びその使用
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
US11578129B2 (en) 2019-03-29 2023-02-14 Boehringer Ingelheim International Gmbh LRP5 and PD-1 antagonist anticancer combination therapy
EA202192596A1 (ru) * 2019-03-29 2022-02-14 Бёрингер Ингельхайм Интернациональ Гмбх Противораковая комбинированная терапия
CA3139061A1 (en) 2019-05-04 2020-11-12 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof
MA55910A (fr) * 2019-05-08 2022-03-16 2Seventy Bio Inc Immunothérapies ciblant cd123
CN119798435A (zh) * 2019-08-14 2025-04-11 安托拉诊疗公司 与lrp5蛋白结合的抗体及使用方法
EP4013790A4 (en) * 2019-08-14 2023-08-23 Modmab Therapeutics Inc. ANTIBODIES BINDING TO LRP6 PROTEINS AND METHODS OF USE THEREOF
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
WO2021163490A1 (en) * 2020-02-14 2021-08-19 University Of Washington Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion
WO2022204316A2 (en) * 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
US20240391997A1 (en) * 2021-07-16 2024-11-28 Brightpath Biotherapeutics Co., Ltd. Anti-tim-3 antigen antibody or antibody derivative, and use thereof
AU2023421423A1 (en) * 2023-01-05 2025-07-17 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer
CN116375851B (zh) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
JP2003531590A (ja) 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
RU2007117752A (ru) 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
CN101248087B (zh) 2005-05-18 2012-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
WO2007140410A2 (en) * 2006-05-30 2007-12-06 Van Andel Research Institute Low-density lipoprotein receptor 6 (lrp6) as a mammary stem cell marker and related methods
WO2007142298A1 (ja) 2006-06-08 2007-12-13 Nsk Ltd. シールリング付シェル型ニードル軸受及びその製造方法
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN100428934C (zh) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
US20100254980A1 (en) 2007-11-02 2010-10-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8661423B2 (en) 2009-05-01 2014-02-25 Telcordia Technologies, Inc. Automated determination of quasi-identifiers using program analysis
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
WO2011075861A1 (en) 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
WO2011119661A1 (en) * 2010-03-24 2011-09-29 Genentech, Inc. Anti-lrp6 antibodies
CN103038258B (zh) 2010-05-06 2017-02-15 诺华股份有限公司 用于治疗低密度脂蛋白相关蛋白质6(lrp6)的抗体的组合物及使用方法
CA2798390A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
CA2812785A1 (en) * 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
KR20240033183A (ko) 2011-06-23 2024-03-12 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
UY34254A (es) 2011-08-17 2013-04-05 Glaxo Group Ltd Proteínas y péptidos modificados.
CA2854457A1 (en) 2011-11-04 2013-05-10 David Jenkins Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
JP5949270B2 (ja) 2012-07-24 2016-07-06 富士通株式会社 オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム
EP2888279A1 (en) * 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
PE20181515A1 (es) * 2015-12-04 2018-09-21 Boehringer Ingelheim Int Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales

Also Published As

Publication number Publication date
RS60823B1 (sr) 2020-10-30
CN108289943A (zh) 2018-07-17
AU2016363787B2 (en) 2023-02-02
LT3383425T (lt) 2020-10-12
US11952418B2 (en) 2024-04-09
MX2018006760A (es) 2018-08-01
HK1255725A1 (en) 2019-08-23
IL259119A (en) 2018-06-28
CA3006235A1 (en) 2017-06-08
EP3797790A1 (en) 2021-03-31
IL259119B (en) 2022-04-01
EP3383425A1 (en) 2018-10-10
US20170174762A1 (en) 2017-06-22
PT3383425T (pt) 2020-10-07
UA122079C2 (uk) 2020-09-10
JP2019506841A (ja) 2019-03-14
BR112018010537A2 (pt) 2018-11-13
SI3383425T1 (sl) 2020-11-30
TWI734719B (zh) 2021-08-01
HUE051777T2 (hu) 2021-03-29
US20200199222A1 (en) 2020-06-25
CN108289943B (zh) 2023-06-20
TW201731868A (zh) 2017-09-16
EA201891331A1 (ru) 2018-12-28
CO2018005680A2 (es) 2018-06-12
NZ742037A (en) 2025-07-25
HRP20201528T1 (hr) 2020-12-11
AU2016363787A1 (en) 2018-05-17
US10597449B2 (en) 2020-03-24
KR102802241B1 (ko) 2025-05-07
CY1123454T1 (el) 2022-03-24
EP3383425B1 (en) 2020-07-15
DK3383425T3 (da) 2020-09-28
MY200933A (en) 2024-01-24
PH12018501155B1 (en) 2024-06-28
MA43368A (fr) 2018-10-10
SA518391728B1 (ar) 2022-03-28
JP6728355B2 (ja) 2020-07-22
JP2020178701A (ja) 2020-11-05
ES2821099T3 (es) 2021-04-23
PL3383425T3 (pl) 2021-01-11
MA54648A (fr) 2021-11-10
SG11201804510PA (en) 2018-06-28
KR20180081825A (ko) 2018-07-17
PH12018501155A1 (en) 2019-01-28
MX380414B (es) 2025-03-12
AR106949A1 (es) 2018-03-07
CL2018001384A1 (es) 2018-09-14
WO2017093478A1 (en) 2017-06-08
MA43368B1 (fr) 2020-09-30

Similar Documents

Publication Publication Date Title
PE20181515A1 (es) Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
ECSP17083788A (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
CR20160542A (es) 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET
UY37018A (es) Inhibidores bicíclicos de pad4
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
UY33956A (es) Anticuerpo del factor antitisular humano y sus usos para tratar cáncer
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
MX2015003701A (es) Composiciones para tratamiento.
EP3565555A4 (en) USE OF HEXOKINASE 2 / MITOCHONDRIA DETACHMENT COMPOUNDS FOR THE TREATMENT OF HEXOKINASE 2 (HK2) EXPRESSING CANCERS
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.